15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Nektar Therapeutics, 8 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $65.00 to $192.00 (about 3.0x), a sign of real disagreement on valuation. The average target of $141.67 sits 88% above the current $75.43. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-3.06 next quarter toward $-10.84 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy880%
Hold220%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Nektar Therapeutics.
As of Sep, 8 of 10 firms rate NKTR a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NKTR EPS & revenue forecast
EPS · NEXT QUARTER
$-3.06
Range $-3.53 – $-2.56 · 4 analysts · +137% YoY
Next period, 4 analysts expect Nektar Therapeutics to earn $-3.06 a share (range $-3.53 – $-2.56), versus $-1.29 a year earlier. Full-year consensus is $-8.46, growing to $-10.84 the year after.
REVENUE · NEXT QUARTER
$10.5M
Range $9.9M – $12.0M · 4 analysts · -52% YoY
Revenue is expected to reach $10.5M (range $9.9M – $12.0M), -51.7% year-over-year. Full-year consensus is $41.9M, rising to $57.0M next year.
Top analysts covering Nektar Therapeutics
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NKTR.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$150.00+98.9% to target
Overall win rate
50%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #71
Hold
$65.00-13.8% to target
Overall win rate
53%
+ Follow
#3
Roger Song
Jefferies · Rank #101
Buy
$121.00+60.4% to target
Overall win rate
43%
+ Follow
#4
Arthur He
HC Wainwright & Co. · Rank #157
Buy
$185.00+145.3% to target
Overall win rate
50%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$192.00+154.5% to target
Overall win rate
33%
+ Follow
NKTR stock forecast FAQ
What is NKTR's average 12-month price target?+
The 9 analysts with a live target average $141.67 for Nektar Therapeutics over the next 12 months, ranging from a $192.00 high to a $65.00 low.
Is NKTR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 8 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NKTR?+
The Street-high target is $192.00 (Piper Sandler), and the Street-low is $65.00 (JP Morgan). The average of all 9 active targets is $141.67.
How many Wall Street analysts cover NKTR?+
10 analysts have an active rating on Nektar Therapeutics, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering NKTR?+
Among analysts who currently cover NKTR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $150.00 target.
What is Nektar Therapeutics's projected EPS for next quarter?+
The consensus estimate is $-3.06 per share (range $-3.53 – $-2.56) across 4 analysts. Full-year EPS is projected at $-8.46, rising to $-10.84 the following year.
How much revenue is Nektar Therapeutics expected to report next quarter?+
Consensus revenue is $10.5M (range $9.9M – $12.0M). Full-year revenue is projected at $41.9M, growing to $57.0M next year.
Have analysts been upgrading or downgrading NKTR lately?+
As of Sep, 8 of 10 firms rate NKTR a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NKTR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
